Horizon Pharma (HZNP) Tops Q1 EPS by 18c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
May 8, 2019 7:04 AM EDT
-- First-Quarter 2019 Net Sales of $280.4 Million Increased 25
Percent;
First-Quarter 2019 GAAP Net Loss of $32.9 Million;
Adjusted EBITDA of $88.4 Million --
-- Quarterly Orphan and Rheumatology Segment Net Sales Increased 8 Percent to $185.9 Million --
-- Increasing Full-Year 2019 Net Sales Guidance Range to $1.26
Billion to $1.28 Billion and
Adjusted EBITDA Guidance Range
to $450 Million to $465 Million,
Including the Impact of
Incremental Investment in Teprotumumab--
-- Announced Phase 3 Teprotumumab Results That Demonstrate a
Dramatic
Reduction in Proptosis in Patients with Active... More
